Study Reveals Efgartigimod’s Effectiveness for Rare Muscle Disease

Researchers at the UNC School of Medicine have successfully led an international clinical trial indicating that efgartigimod, an FDA-approved therapy, is both safe and effective for patients with all subtypes of generalized myasthenia gravis (gMG). This neuromuscular disorder leads to moderate to severe muscle weakness and can significantly disrupt daily activities, including work and social interactions.

The findings were unveiled at the Annual Scientific Session of the Myasthenia Gravis Foundation of America, which took place in San Francisco from October 29 to November 1, 2025. The trial, known as the ADAPT SERON study, represents the largest of its kind and provides critical insights into treatment options for patients who have limited choices.

Trial Details and Outcomes

Until recently, there was little understanding of how efgartigimod functioned across various subtypes of gMG, particularly since this condition can manifest differently based on the types of antibodies present in patients. James F. Howard Jr., MD, a leading expert on myasthenia gravis and principal investigator of the trial, emphasized the importance of these results. “The results of this study confirm that this medication now has the potential to be a targeted, effective, safe, and necessary treatment for patients, regardless of autoantibody status,” he stated.

The trial involved participants from North America, Europe, China, and the Middle East, who received either four weekly infusions of efgartigimod or a placebo, followed by additional open-label treatment. Ultimately, 119 patients treated with efgartigimod showed significant improvements in their quality of life as measured by the Myasthenia Gravis Activities of Daily Living (MG-ADL) score, which assesses essential functions like speaking, swallowing, and limb strength.

Future Implications for Treatment

In light of these promising results, argenx, the drug’s manufacturer, intends to submit a Supplemental Biologic License Application to the FDA. This application aims to broaden the treatment’s label to encompass cases of MuSK-positive, LRP4-positive, and triple seronegative gMG, potentially expanding access to thousands more individuals affected by this debilitating condition.

Generalized myasthenia gravis occurs when antibodies produced by the immune system mistakenly target the communication points between nerves and muscles, leading to fluctuating muscle weakness and fatigue. Efgartigimod works by reducing the harmful antibodies that disrupt this nerve-muscle communication. The most prevalent subtype of gMG is AChR antibody-positive, characterized by antibodies against acetylcholine receptors, which are crucial for voluntary muscle movement.

The ADAPT SERON study is a significant step forward in understanding and treating gMG, bringing hope to patients who face daily challenges due to this unpredictable disease. As more data emerges, the medical community anticipates that efgartigimod will play a pivotal role in the management of gMG across its various subtypes.

For detailed information on the trial, visit clinicaltrials.gov/study/NCT06298552.